Sept 25 (Reuters) - BioAge Labs is eyeing a valuation of

up to $639.7 million in its upsized initial public offering in

the United States, the obesity drug developer said on Wednesday,

in a sign of strong demand from investors.

The Richmond, California-based company is now seeking to

raise as much as $199.5 million by offering 10.5 million shares

at $17 to $19 each.

The company had earlier planned on offering 7.5 million

shares at the same price range.

BioAge Labs will list on the Nasdaq Global Market under the

symbol "BIOA".

Goldman Sachs, Morgan Stanley, Jefferies and Citigroup are

the underwriters for the offering.